<DOC>
	<DOC>NCT00457457</DOC>
	<brief_summary>This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate. Patients will complete a series of questionnaires before, during and after treatment to assess if UK-369,003 has improved their urinary symptoms and erectile function . There will be several blood samples taken during the study to asses the level of drug in the blood and correlate it with the responses to the questionnaires.</brief_summary>
	<brief_title>Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>1. Male subjects aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ≥13 2. Clinical diagnosis of BPH. 3. Qmax 5 to 15ml/sec with a voided volume of ≥150ml at visit 1 (screening). 1. Urinary tract infection 2. Primary neurological conditions affecting bladder function</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>With or without erectile dysfunction</keyword>
</DOC>